• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [16861 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2019     NIHR Health Services and Delivery Research programme Innovation to enhance health in care homes: rapid evidence synthesis
2019     NIHR Health Technology Assessment programme A peer-led physical activity intervention in schools for adolescent girls: a feasibility RCT
2019     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Transmural fixation of aortic endograft adjunct to endovascular aneurysm repair using helical anchors
2019     NIHR Health Technology Assessment programme MRI in the diagnosis of fetal developmental brain abnormalities: the MERIDIAN diagnostic accuracy study
2019     NIHR Health Technology Assessment programme Intravenous co-amoxiclav to prevent infection after operative vaginal delivery: the ANODE RCT
2019     NIHR Health Services and Delivery Research programme Improving NHS quality using internet ratings and experiences (INQUIRE)
2019     Agency for Healthcare Research and Quality (AHRQ) Achieving health equity in preventive services
2019     NIHR Health Technology Assessment programme Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT
2019     Agency for Healthcare Research and Quality (AHRQ) Addressing social isolation to improve the health of older adults: a rapid review
2019     NIHR Health Technology Assessment programme Anal fistula plug versus surgeon's preference for surgery for trans-sphincteric anal fistula: the FIAT RCT
2019     NIHR Health Services and Delivery Research programme Evaluation of specialist nursing support for carers of people with dementia
2019     Agency for Healthcare Research and Quality (AHRQ) Adverse effects of pharmacological treatments of major depression in older adults
2019     NIHR Health Services and Delivery Research programme Understanding and enhancing how hospital staff learn from and act on patient experience data
2019     Agency for Healthcare Research and Quality (AHRQ) Antipsychotics for the prevention and treatment of delirium
2019     NIHR Health Services and Delivery Research programme A study of sense-making strategies and help-seeking behaviours associated with the use and provision of urgent care services
2019     NIHR Health Technology Assessment programme Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study
2019     NIHR Health Technology Assessment programme Refusal and resistance to care by people living with dementia being cared for within acute hospital wards: an ethnographic study
2019     The Regional Health Technology Assessment Centre (HTA-centrum) Efficacy of sleep deprivation in patients with depression including bipolar depression
2019     NIHR Health Technology Assessment programme A school-based intervention ('Girls Active') to increase physical activity levels among 11- to 14-year-old girls: cluster RCT
2019     Penn Medicine Center for Evidence-based Practice (CEP) The Effect of Patient Communication About Medical Errors on Malpractice Lawsuits
2019     The Regional Health Technology Assessment Centre (HTA-centrum) Effectiveness and safety of microsurgical testicular sperm extraction in infertile men with non-obstructive azoospermia
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk
2019     Penn Medicine Center for Evidence-based Practice (CEP) Interventions to Reduce the Use of the High Risk Medications in Elderly Patients
2019     The Regional Health Technology Assessment Centre (HTA-centrum) Gene expression profiles to guide adjuvant chemotherapy in luminal, HER2-negative breast cancer
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis
2019     Penn Medicine Center for Evidence-based Practice (CEP) Guidelines for Supplementary Feedings of Newborn Infants
2019     The Regional Health Technology Assessment Centre (HTA-centrum) Impact of postmastectomy radiotherapy on complications and results of immediate breast reconstruction
2019     NIHR Health Technology Assessment programme Developing an intervention around referral and admissions to intensive care: a mixed-methods study
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease). EUnetHTA-Report
2019     The Regional Health Technology Assessment Centre (HTA-centrum) EEG-based neurofeedback as treatment for post-traumatic stress disorder
2019     NIHR Health Technology Assessment programme Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer
2019     The Regional Health Technology Assessment Centre (HTA-centrum) Trabecular bone pattern assessment in dental radiographs for prediction of bone fracture risk
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triple-negative breast cancer (aTNBC)
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections. EUnetHTA-Report
2019     NIHR Health Technology Assessment programme Treatment of first-time traumatic anterior shoulder dislocation UK.TASH-D Study
2019     Agency for Healthcare Research and Quality (AHRQ) Comparative effectiveness of analgesics to reduce acute pain in the prehospital setting
2019     National Institute for Health and Care Excellence (NICE) UrgoStart for treating diabetic foot ulcers and leg ulcers. NICE medical technologies guidance 42
2019     NIHR Health Services and Delivery Research programme The changing general practitioner workforce: the development of policies and strategies aimed at retaining experienced GPs and those taking a career break in direct patient care (ReGROUP)
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Robot-assisted surgery in thoracic and visceral indications
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC)
2019     National Institute for Health and Care Excellence (NICE) Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2. NICE highly specialised technologies guidance 12
2019     National Institute for Health and Care Excellence (NICE) Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations. NICE highly specialised technologies guidance 11
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Single/two-step scaffold-based cartilage repair in the knee and ankle joint
2019     Agency for Care Effectiveness (ACE) Video capsule endoscopy for diagnosing obscure gastrointestinal bleeding
2019     National Institute for Health and Care Excellence (NICE) Patisiran for treating hereditary transthyretin amyloidosis. NICE highly specialised technologies guidance 10
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Radiofrequency denervation for lumbar and cervical facet joint pain – a systematic review
2019     National Institute for Health and Care Excellence (NICE) Inotersen for treating hereditary transthyretin amyloidosis. NICE highly specialised technologies guidance 9
2019     Agency for Care Effectiveness (ACE) Home Sleep Test for diagnosing obstructive sleep apnoea
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Osteochondral allograft transplantation for the knee (or other joints)
2019     NIHR Health Technology Assessment programme Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Allograft for anterior and posterior cruciate ligament reconstruction
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Human dermal allograft for massive rotator cuff tears
2019     NIHR Health Services and Delivery Research programme PRESENT: Patient Reported Experience Survey Engineering of Natural Text: developing practical automated analysis and dashboard representations of cancer survey freetext answers
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate
2019     NIHR Health Technology Assessment programme Stepped approach to improving sexual function after gynaecological cancer: the SAFFRON feasibility RCT
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Custom-made or customisable 3D printed implants and cutting guides versus non- 3D printed standard implants and cutting guides for improving outcome in patients undergoing knee, maxillofacial, or cranial surgery
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs)
2019     National Institute for Health and Care Excellence (NICE) Regorafenib for previously treated advanced hepatocellular carcinoma. NICE technology appraisal guidance 555
2019     NIHR Health Technology Assessment programme Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Irreversible electroporation for the treatment of liver and pancreatic cancer
2019     National Institute for Health and Care Excellence (NICE) Darvadstrocel for treating complex perianal fistulas in Crohn's disease. NICE technology appraisal guidance 556
2019     NIHR Health Technology Assessment programme Anaesthetic analgesic ear drops to reduce antibiotic consumption in children with acute otitis media: the CEDAR RCT
2019     National Institute for Health and Care Excellence (NICE) Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal). NICE technology appraisal guidance 560
2019     Institute of Health Economics (IHE) Clinical effectiveness and cost-effectiveness of Oncotype DX and Prosigna genetic testing in early-stage breast cancer
2019     National Institute for Health and Care Excellence (NICE) Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia. NICE technology appraisal guidance 561
2019     Health Information and Quality Authority (HIQA) Clinical and cost-effectiveness of the National Early Warning System (NEWS): a systematic review update. The Irish National Early Warning System (NEWS) National Clinical Guideline No. 1
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Public & philanthropic financial contribution to the development of new drugs: Methodology & 3 Case Studies
2019     National Institute for Health and Care Excellence (NICE) Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma. NICE technology appraisal guidance 562
2019     National Institute for Health and Care Excellence (NICE) Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. NICE technology appraisal guidance 563
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)
2019     National Institute for Health and Care Excellence (NICE) Benralizumab for treating severe eosinophilic asthma. NICE technology appraisal guidance 565
2019     NIHR Health Technology Assessment programme Manualised cognitive behavioural therapy in treating depression in advanced cancer: the CanTalk RCT
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Sponsoring of Patient Initiatives in Austria 2018. Update of the Systematic Analyses 2014, 2015 and 2016
2019     National Institute for Health and Care Excellence (NICE) Cochlear implants for children and adults with severe to profound deafness. NICE technology appraisal guidance 566
2019     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. NICE technology appraisal guidance 567
2019     NIHR Health Technology Assessment programme Cabozantinib and vandatinib for treating advanced or metastatic medullary thyroid cancer (ID56)
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC)
2019     National Institute for Health and Care Excellence (NICE) Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal). NICE technology appraisal guidance 568
2019     National Institute for Health and Care Excellence (NICE) Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer. NICE technology appraisal guidance 569
2019     Agency for Healthcare Research and Quality (AHRQ) Long-term drug therapy and drug holidays for osteoporosis fracture prevention: a systematic review
2019     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 570
2019     NIHR Health Technology Assessment programme An evaluation of the feasibility of conducting a randomised clinical trial to evaluate the clinical and cost-effectiveness of a more permissive temperature threshold for antipyretic intervention in critically ill children with fever due to infection: the FEVER feasibility study
2019     National Institute for Health and Care Excellence (NICE) Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib. NICE technology appraisal guidance 571
2019     NIHR Health Technology Assessment programme Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluation
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) POCT/ Point of Care Tests: D-Dimer and Troponin
2019     National Institute for Health and Care Excellence (NICE) Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes. NICE technology appraisal guidance 572
2019     Medical Services Advisory Committee (MSAC) Digital breast tomosynthesis
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Minimum volume standards for quality assurance in day surgery: Fundamentals and Systematic Review
2019     Penn Medicine Center for Evidence-based Practice (CEP) Pulmonary Artery Catheters Catheter Dwell Time and Routine Replacement
2019     National Institute for Health and Care Excellence (NICE) Certolizumab pegol for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 574
2019     NIHR Health Technology Assessment programme Early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration: the EVRA RCT
2019     Penn Medicine Center for Evidence-based Practice (CEP) Dual Antiplatelet Therapy Following Revascularization for Peripheral Artery Disease
2019     National Institute for Health and Care Excellence (NICE) Tildrakizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 575
2019     NIHR Health Technology Assessment programme Electronically delivered interventions to reduce antibiotic prescribing for respiratory infections in primary care: cluster RCT using electronic health records and cohort study
2019     Penn Medicine Center for Evidence-based Practice (CEP) Dosing of Botulinum Toxin for Neurologic Indications
2019     National Institute for Health and Care Excellence (NICE) Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal). NICE technology appraisal guidance 576
2019     Penn Medicine Center for Evidence-based Practice (CEP) Management of Tunneled Dialysis Catheters in Patients with Bloodstream Infection
2019     Agency for Healthcare Research and Quality (AHRQ) Management of infertility
2019     National Institute for Health and Care Excellence (NICE) Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma. NICE technology appraisal guidance 577